pharma · Diphtheria · Diabetes Mellitus, Type 2
Sanofi Pasteur MSD
Sanofi Pasteur
Sanofi Pasteur is a pharma organization headquartered in LYON, FR. Primary therapeutic focus areas include Diphtheria, Diabetes Mellitus, Type 2, Japanese Encephalitis, Rabies, Hemophilia A. NovaPharmaNews links 83 clini
France, LYON HQ
363 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- France, LYON
- Employees
- 363
- Programs
- 83
- Drugs
- 66
- Patents
- 0
Isatuximab
Phase 2 · small molecule · Relapsed/Refractory Multiple Myeloma
Isatuximab for Relapsed/Refractory Multiple Myeloma is a Phase 2 program (small_molecule) at Sanofi Pasteur with 1 ClinicalTrials.gov record(s).
Internal code ACT17453
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Sanofi Pasteur
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Relapsed/Refractory Multiple Myeloma
- Status
- active
- Trials
- 1